- Home
- AIRS vs VIGL Comparison
AIRS vs VIGL Comparison
Compare AIRS & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- VIGL
- Stock Information
- Founded
- AIRS 2012
- VIGL 2020
- Country
- AIRS United States
- VIGL United States
- Employees
- AIRS N/A
- VIGL N/A
- Industry
- AIRS Medical/Nursing Services
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- AIRS Health Care
- VIGL Health Care
- Exchange
- AIRS Nasdaq
- VIGL Nasdaq
- Market Cap
- AIRS 166.3M
- VIGL 134.9M
- IPO Year
- AIRS 2021
- VIGL 2022
- Fundamental
- Price
- AIRS $6.22
- VIGL $8.05
- Analyst Decision
- AIRS Hold
- VIGL Buy
- Analyst Count
- AIRS 3
- VIGL 7
- Target Price
- AIRS $3.75
- VIGL $8.00
- AVG Volume (30 Days)
- AIRS 626.7K
- VIGL 697.0K
- Earning Date
- AIRS 08-01-2025
- VIGL 08-12-2025
- Dividend Yield
- AIRS N/A
- VIGL N/A
- EPS Growth
- AIRS N/A
- VIGL N/A
- EPS
- AIRS N/A
- VIGL N/A
- Revenue
- AIRS $172,101,000.00
- VIGL N/A
- Revenue This Year
- AIRS N/A
- VIGL N/A
- Revenue Next Year
- AIRS $4.90
- VIGL N/A
- P/E Ratio
- AIRS N/A
- VIGL N/A
- Revenue Growth
- AIRS N/A
- VIGL N/A
- 52 Week Low
- AIRS $1.53
- VIGL $1.31
- 52 Week High
- AIRS $9.20
- VIGL $8.10
- Technical
- Relative Strength Index (RSI)
- AIRS 63.97
- VIGL 80.91
- Support Level
- AIRS $6.15
- VIGL $8.03
- Resistance Level
- AIRS $6.72
- VIGL $8.09
- Average True Range (ATR)
- AIRS 0.47
- VIGL 0.02
- MACD
- AIRS 0.04
- VIGL -0.08
- Stochastic Oscillator
- AIRS 75.67
- VIGL 60.00
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.